Results
21
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
21 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ADOC | €6.52 | 15.4% | 68.5% | €98.1m | €6.30 | PS16.2x | E63.0% | n/a | Pharmaceuticals & Biotech | ||
ALOKW | €19.28 | 1.6% | -24.1% | €159.3m | €30.30 | PE21.1x | E30.8% | n/a | Capital Goods | ||
VU | €140.90 | -0.4% | 8.2% | €2.2b | €195.20 | PE28.1x | E25.2% | 0.2% | Tech | ||
OSE | €6.83 | 0.4% | 95.7% | €148.6m | €10.15 | PS66.7x | E5.9% | n/a | Pharmaceuticals & Biotech | ||
FDE | €29.25 | -4.3% | -30.0% | €153.0m | €60.33 | PE19.5x | E31.9% | n/a | Energy | ||
ALMUN | €0.48 | -4.0% | -83.9% | €4.3m | €1.30 | PB0.3x | E149.2% | n/a | Tech | ||
ALCUR | €6.72 | 4.7% | 169.9% | €38.7m | €8.48 | PE21.5x | E27.5% | n/a | Capital Goods | ||
ALICA | €10.65 | 8.7% | -26.0% | €86.1m | €16.00 | PE15.7x | E26.2% | 1.9% | Tech | ||
MEDCL | €14.82 | -0.1% | 135.6% | €430.7m | €20.70 | PS36.1x | E69.6% | n/a | Pharmaceuticals & Biotech | ||
ALSMA | €3.98 | 4.5% | 54.3% | €20.8m | €5.80 | PE19.6x | E35.2% | n/a | Healthcare | ||
S30 | €1.72 | 4.2% | -43.1% | €183.9m | €2.75 | PB1.7x | E101.6% | n/a | Software | ||
ALLIX | €6.40 | -22.4% | -42.3% | €41.6m | €16.00 | PS1.2x | E101.6% | n/a | Software | ||
CLA | €1.85 | -3.0% | 5.8% | €105.0m | €4.75 | PE-21x | E90.6% | n/a | Software | ||
ALECP | €0.35 | 2.0% | -31.9% | €43.1m | n/a | PE47.9x | E86.8% | 0% | Media | ||
ALCIS | €8.58 | 0% | -16.7% | €66.8m | €12.10 | PE20.9x | E56.5% | 1.9% | Commercial Services | ||
ATEME | €4.00 | 0% | -57.9% | €46.0m | €8.00 | PB1.2x | E96.4% | n/a | Tech | ||
ALHOP | €21.90 | 2.3% | 23.0% | €62.9m | €30.05 | PE13.8x | E21.6% | 3.0% | Media | ||
LSS | €28.90 | -1.7% | 8.0% | €1.1b | €34.75 | PE32.7x | E28.6% | 1.2% | Software | ||
OVH | €5.70 | 3.3% | -40.2% | €1.1b | €9.20 | PS1.1x | E103.7% | n/a | Software | ||
ALPAT | €14.40 | 2.9% | 12.5% | €15.9m | €11.50 | n/a | E92.7% | n/a | Pharmaceuticals & Biotech | ||
EXN | €23.25 | 0.4% | 20.7% | €2.1b | €24.50 | PE48.8x | E28.4% | 0% | Software |